The thiazolidinediones are the insulin sensitizers used in the management of Type 2 diabetes mellitus. These drugs can potentially
decrease the risk of cardiovascular disease by correcting the different components of the insulin resistance syndrome.
The authors have stated that they do not have a significant financial interest or other relationship with any product manufacturer
or provider of services discussed in this article.